Ten-year outcomes: The clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 1, 2011, Pages 29-34

  Ellis, Rodney J ^a   Kaminsky, Deborah A ^b   Zhou, Esther H ^c   Fu, Pingfu ^d   Chen, Wei Dong ^e   Brelin, Alaina ^f   Faulhaber, Peter F ^d   Bodner, Donald ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b AULTMAN HOSPITAL   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Capromab pendetide; Image guided radiotherapy; Prostascint; Prostate specific membrane antigen; Staging

Indexed keywords

CAPROMAB PENDETIDE; IMAGE GUIDED RADIOTHERAPY; PROSTASCINT; PROSTATE-SPECIFIC MEMBRANE ANTIGENS; STAGING;

DIAGNOSIS; DISEASES; MULTIVARIANT ANALYSIS; NUCLEAR MEDICINE; PARTICLE BEAMS; PHOTONS; RADIOTHERAPY; TOMOGRAPHY;

SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

CAPROMAB PENDETIDE IN 111;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SURVIVOR; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE ESCALATION; HIGH RISK POPULATION; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; INDIUM RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79961127983     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.05.053     Document Type: Article

References (28)

1. A. Jenal, R. Siegel, and E. Ward Cancer statistics CA Cancer J Clin 59 2009 225 249
2. G.J. Kelloff, and P. Choyke Coffey DS for the Prostate Cancer Imaging Working Group. Challenges in clinical prostate cancer: Role of imaging AJR Am J Roentgenol 192 2009 1455 1468
3. K.E. Thompson, J. Hernandez, and E.D. Canby-Hagino Prognostic features in men who died of prostate cancer J Urol 174 2005 553 556 discussion 556 (Pubitemid 40981599)
4. N.N. Stone, L. Potters, and B.J. Davis Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2009 341 346
5. G.L. Wright Jr., C. Haley, and M.L. Becket Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues Urol Oncol 1 1995 18 28
6. J.S. Ross, C.E. Sheehan, and H.A.G. Fisher Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer Clin Cancer Res 9 2003 6357 6362 (Pubitemid 38031820)
7. Prostascint [package insert] 1997 Cytogen Corporation Princeton, NJ
8. D.B. Sodee, R.J. Ellis, and M.A. Samuels Prostate cancer and prostate bed SPECT imaging with prostascint: Semiquantitative correlation with prostatic biopsy results Prostate 37 1998 140 148 (Pubitemid 28487897)
9. D.B. Sodee, N. Malguria, and P. Faulhaber Multicenter prostascint imaging findings in 2154 patients with prostate cancer Urology 20 56 2000 988 993
10. R.J. Ellis, A. Vertocnik, and E. Kim Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma Int J Radiat Oncol Biol Phys 57 2003 362 370 (Pubitemid 37040931)
11. R.J. Ellis, and D.A. Kaminsky Fused radioimmunoscintigraphy for treatment planning Rev Urol 8 Suppl 2006 11 19
12. R.J. Ellis, E.H. Zhou, and P. Fu SPECT CT capromab pendetide independently predicts biochemical failure J Urol 179 2008 1768 1774
13. R.J. Ellis, H. Zhou, and E. Kim Rectal morbidity following permanent prostate brachytherapy with dose escalation to biological target volumes identified by SPECT/CT fusion Brachytherapy 6 2007 149 156 (Pubitemid 46551965)
14. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
15. Consensus statement Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel Int J Radiat Oncol Biol Phys 37 1997 1035 1041
16. M.W. Kattan Judging new markers by their ability to improve predictive accuracy (editorial) J Natl Cancer Inst 95 2003 634 635 (Pubitemid 36603708)
17. W.W. Wong, S.E. Schild, and S.A. Vora Intensity modulated radiation therapy (IMRT) for prostate cancer: Phase I/II study of concomitant boost using Indium in 111 capromab pendetide (Prostascint) imaging (abstract) Int J Radiat Oncol Biol Phys 75 Suppl 2009 319 320
18. R.J. Ellis, E.Y. Kim, and R. Conant Radioimmunoguided imaging of prostate cancer foci with histopathological correlation Int J Radiat Oncol Biol Phys 49 2001 1281 1286 (Pubitemid 32294309)
19. V. Mouraviev, J.F. Madden, and G. Broadwater Use of 111In-capromab pendetide immunoscintigraphy to image localized prostate cancer foci J Urol 182 2009 938 948
20. M.K. Haseman, S.A. Rosenthal, and S.I. Kipper Central abdominal uptake of indium-111 capromab pendetide (prostascint) predicts for poor prognosis in patients with prostate cancer Urology 70 2007 303 308 (Pubitemid 47362258)
21. C.E. Bermejo, J. Coursey, and J. Basler Histologic confirmation of lesions identified by Prostascint scan following definitive treatment Urol Oncol 21 2003 349 353
22. L.E. Ponsky, E.E. Cherullo, and R. Starkey Evaluation of preoperative prostacint scans in the prediction of nodal disease Prostate Cancer Prostatic Dis 5 2002 132 135 (Pubitemid 34777897)
23. C.J. Schettino, E.L. Kramer, and M.E. Noz Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer AJR Am J Roentgenol 183 2004 519 524 (Pubitemid 38970350)
24. S.N. Nagda, N. Mohideen, and S.S. Lo Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer Int J Radiat Oncol Biol Phys 67 2007 834 840 (Pubitemid 46215867)
25. G.V. Raj, A.W. Partin, and T.J. Polascik for the ProstaScint Study Group. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early recurrent prostate carcinoma after radical prostatectomy Cancer 17 2002 43 48
26. A.B. Jani, M.J. Blend, and R. Hamilton Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control J Nucl Med 45 2004 1315 1322 (Pubitemid 47618529)
27. R.J. Ellis, and D.A. Kaminsky inventors; Advanced Clinical Solutions, Inc. (ACSI), assignee. Method of Defining a Biological Target for Treatment US Patent Application Publication No. 20060258933 November 16, 2006
28. R.J. Ellis, D.A. Kaminsky, and H. Zhou Molecular image validation utilizing the correlation of histopathology and marker placement system (CHAMPS) protocol [abstract] Int J Radiat Oncol Biol Phys 66 Suppl 2006 360